Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ponalrestat SCHEMBL29498248 | 1.00 | AKR1B1 (1.00) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| Ponalrestat SCHEMBL30350285 | 1.00 | AKR1B1 (1.00) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11175078 | 0.90 | AKR1B1 (0.82) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| Ponalrestat SCHEMBL11166654 | 0.89 | AKR1B1 (0.80) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| Ponalrestat SCHEMBL10702188 | 0.89 | AKR1B1 (0.80) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL9218514 | 0.89 | AKR1B1 (0.80) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11172039 | 0.88 | AKR1B1 (0.79) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11167901 | 0.88 | AKR1B1 (0.78) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL9321689 | 0.88 | AKR1B1 (1.00) | AKR1B1MEN1CYP1A2CYP2C9KMT2A | |
| SCHEMBL11165597 | 0.87 | AKR1B1 (0.77) | AKR1B1MEN1CYP1A2CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | claimed |
| US-20240374693-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2024-11-14 | — | — | US | claimed |
| US-12083168-B2 | Treatment and detection of inherited neuropathies and associated disorders | UNIVERSITY OF MIAMI (US) | 2024-09-10 | — | — | US | claimed |
| US-20240003908-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-01-04 | — | — | US | claimed |
| US-20230293642-A9 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2023-09-21 | — | — | US | claimed |
| EP-4244243-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | Mayo Foundation for Medical Education and Research (US) | 2023-09-20 | — | — | EP | claimed |
| US-20220249624-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIV MIAMI (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022103815-A1 | POLYOL BIOMARKERS FOR CONGENITAL DISORDERS OF GLYCOSYLATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAGGIES PEARL LLC (US) | 2022-04-28 | — | — | US | claimed |
| US-20220125890-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2022-04-28 | — | — | US | claimed |
| EP-0224352-B1 | OCULAR TREATMENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-29 | — | — | EP | claimed |
| US-4952212-A | Ocular treatment | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-28 | — | — | US | claimed |
| US-4910022-A | Blend with microcrystalline cellulose and binder | MERCK & CO., INC. (US) | 1990-03-20 | — | — | US | claimed |
| US-4895843-A | URIC ACID BLOOD LEVEL REDUCTION | ICI AMERICAS, INC. (US) | 1990-01-23 | — | — | US | claimed |
| EP-0315249-A1 | Phthalazineacetic acid composition and tablet | MERCK & CO. INC. (US) | 1989-05-10 | — | — | EP | claimed |
| EP-0296695-A2 | Hypouricaemic agent containing ponalrestat | ICI AMERICAS INC. (US) | 1988-12-28 | — | — | EP | claimed |
| EP-0224352-A1 | Ocular treatment | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-03 | — | — | EP | claimed |
| US-4393062-A | ALDOSE REDUCTASE INHIBITOR | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-07-12 | — | — | US | claimed |
| EP-0002895-B1 | ENZYME INHIBITORY PHTHALAZIN-4-YLACETIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESS FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | claimed |
| US-4251528-A | ALDOSE REDUCTASE INHIBITORS USEFUL IN DIABETES, GALACTOSEMIA | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | KHK, GCK, FN3K | AKR1B1 277/4885MEN1 3061/4885CYP1A2 2953/4885 |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAN1B1, MAN2B1, GAA | AKR1B1 1383/4885MEN1 3057/4885CYP1A2 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.